Jeb Keiper is moving up to the CEO post at Nimbus.
The high-profile biotech says Keiper, who joined Nimbus in 2014 as head of business development, played a big role in forging deals and financing rounds that brought in $775 million — including a blockbuster $400 million cash deal with Gilead for its NASH program.
It looks like we haven’t seen the last of founding CEO Don Nicholson. In a statement, Nicholson said he was looking forward to moving on to the “next entrepreneurial chapter of my career,” wishing Keiper continued success with his move up.
Nicholson’s departure from the computational drug discovery company comes 7 months after Rosana Kapeller left her role as founding CSO, also discussing a move to a new executive position. So far there’s been no new word on where she might land, though she did jump on the board at Cedilla a few months ago.
Keiper is a familiar face in biotech. He completed a lengthy stint doing BD for GSK, including running the deal team for the oncology group, a once busy shop.
Cambridge, MA-based Nimbus chairman Bruce Booth — a marquee investor at Atlas — signed off with the usual pleasantries, adding that he was looking forward to working with Nicholson on other ventures.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,200+ biopharma pros who read Endpoints News by email every day.Free Subscription